Haptoglobin 2-2 phenotype is associated with decreased ferroxidase activity in smokers

Clinica Chimica Acta

Volumn 334, Issue 1-2, 2003, Pages 71-76

  Awadallah, Samir M ^a  

^a HASHEMITE UNIVERSITY   (Jordan)

Author keywords

Cardiovascular diseases; Ferroxidase; Haptoglobin; Jordan; Lipid profile; Smokers

Indexed keywords

CERULOPLASMIN; HAPTOGLOBIN; LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; HUMAN; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE;

JORDANIA;

EID: 12444300072     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00164-5     Document Type: Article

References (38)

1. Giblett E.R. The haptoglobin system. Ser. Haematol. 1:1968;3-20.
2. Agil A., Fuller C.J., Jialal I. Susceptibility of plasma to ferrous iron/hydrogen peroxide-mediated oxidation: demonstration of a possible Fenton reaction. Clin. Chem. 41:1995;220-225.
3. Gutteridge J.M.C. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 41:1995;1819-1828.
4. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42:1996;1589-1600.
5. Javid J. The effect of haptoglobin-polymer size on hemoglobin-polymer size on hemoglobin binding capacity. Vox Sang. 10:1965;320-325.
6. Lange V. Der Haptoglobin polymorphismus-nicht nur eine genetische Markieungshilfe. [Review] Antropol. Anz. 50:1992;281-302.
7. Langlois M.R., Delanghe J.R., De Buyzere M.L., Bernard D.R., Ouyang J. Effect of haptoglobin on metabolism of vitamin C. Am. J. Clin. Nutr. 66:1997;606-610.
8. Langlois M.R., Martin M.E., Boelaert J.R.et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin. Chem. 46:2000;1619-1625.
9. Fröhlander N. Haptoglobin groups and serum cholesterol levels. Human. Hered. 37:1987;323-325.
10. Saha N., Liu Y., Tay J.S.H., Basair J., Cho C.H. Association of haptoglobin types with serum lipids and apolipoproteins in Chinese population. Clin. Genet. 42:1992;57-61.
11. Delanghe J., Duprez D., De Buyzere M.et al. Haptoglobin polymorphism and complications in established arterial hypertension. J. Hypertens. 11:1993;861-867.
12. Delanghe J., Duprez D.A., De Buyzere M.L.et al. Refractory hypertension is associated with haptoglobin 2-2 phenotype. J. Cardiol. Risk. 2:1995;131-136.
13. Delanghe J., Cambier B., Langlois M.et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis. 132:1997;215-219.
14. Hong S.H., Kang B.Y., Lim J.H.et al. Haptoglobin polymorphism in Korean patients with cardiovascular diseases. Hum. Hered. 47:1997;283-287.
15. Delanghe J., Langlois M., Duprez D., De Buyzere M., Clement D. Haptoglobin polymorphism and peripheral occlusive disease. Atherosclerosis. 145:1999;287-292.
16. Braeckman L., De Bacquer D., Delanghe J., Claeys L., De Backer G. Association between haptoglobin polymorphism, lipid, lipoprotein and inflammatory variables. Atherosclerosis. 143:1999;383-388.
17. Gutteridge J.M.C. Antioxidant properties of ceruloplasmin towards iron- and copper-dependent oxygen radical formation. FEBS Lett. 157:1983;37-40.
18. Gutteridge J.M. Inhibition of the Fenton reaction by the protein ceruloplasmin and other copper complexes. Assessment of ferroxidase and free radical scavenging activities. Chem. Biol. Interact. 56:1985;113-120.
19. Craig W.Y., Poulin S.E., Palomaki G.E., Neveux L.M., Ritchie R.F., Ledue T.B. Oxidation-related analytes and lipid and lipoproteins concentrations in healthy subjects. Atherosclerosis Thromb. Vasc. Biol. 15:1995;733-739.
20. Craig W.Y., Palomaki G.E., Haddow J.E. Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. BMJ. 298:1989;784-788.
21. Cullen P., Schulte H., Assmann G. Smoking, lipoproteins and coronary heart diseases risk. Data from the Munster Heart Study (PROCAM). Eur. Heart J. 19:1998;1632-1641.
22. Pacht E.R., Davis W.B. Decreased ceruloplasmin ferroxidase activity in cigarette smokers. J. Lab. Clin. Med. 111:1988;661-668.
23. Pacht E.R., Davis W.B. Failure of high-dose vitamin E to correct ceruloplasmin ferroxidase deficiency in cigarette smokers. Am. Rev. Respir. Dis. 142:1990;1063-1067.
24. Duthie G.G., Arthur J.R., James W.P. Effect of smoking and vitamin E on blood antioxidant status. Am. J. Clin. Nutr. 53:1991;1061S-1063S.
25. Dalamaga A.L., Agroyannis B., Vitoratos N.et al. Effect of smoking on ceruloplasmin and its ferroxidase activity in pregnant women. Gynecol. Obstet. Investig. 42:1996;13-15.
26. Schosinsky H., Lehman H.P., Beeler M.F. Measurement of ceruloplasmin from its ferroxidase activity in serum by use of O-dianisidine dihydrochloride. Clin. Chem. 20:1974;1556-1563.
27. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
28. Awadallah S., Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios. 101:2000;145-150.
29. Hamad H., Awadallah S. Age group-associated variations in the pattern of Hp type distribution in Jordanians. Clin. Chim. Acta. 300:2000;75-81.
30. Harats D., Ben-Naim M., Dabach Y., Hollander G., Stein O., Stein Y. Cigarette smoking renders the LDL susceptibility to peroxidation modification and enhance metabolism by macrophages. Atherosclerosis. 79:1989;245-252.
31. Freeman D.J., Griffin B.A., Murray A.et al. Smoking and plasma lipoproteins in man: effect on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur. J. Clin. Investig. 23:1993;630-640.
32. Whitehead T.P., Robinson D., Allaway S.L. The effect of cigarette smoking and alcohol consumption on blood lipids: a dose-related study on men. Ann. Clin. Biochem. 1996;99-106.
33. Thompson R.L., Margetts B.M., Wood D.A., Jackson A.A. Cigarette smoking and food nutrient intake in relation to coronary heart disease. Nutr. Res. Rev. 5:1992;131-152.
34. Mezzetti A., Lapenna D., Pierdomenico S.et al. Vitamin E, C and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis. 112:1995;91-99.
35. Yoshie Y., Ohshima H. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide. Carcinogenesis. 18:1997;1359-1363.
36. Swain J.A., Darley-Usmar V., Gutteridge J.M. Peroxynitrite releases copper from ceruloplasmin: implications for atherosclerosis. FEBS Lett. 442:1994;49-52.
37. Pignatelli B., Li C.Q., Boffetta P.et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res. 61:2001;778-784.
38. Levy A., Roguin A., Hochberg I.et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N. Engl. J. Med. 343:2000;969-970.